Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyung-Hun Lee

Showing results (161-170 of 248) with videos related to

Pageof 25
Sort By:
Cancer Chemotherapy and Pharmacology|May 16, 2013
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancerJi-Won Kim, Jee Hyun Kim, Seock-Ah Im, et al.
British Journal of Cancer|October 14, 2016
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trialsDae-Won Lee, Myoung-Jin Jang, Kyung-Hun Lee, et al.
Breast Cancer Research : BCR|March 4, 2011
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBhumsuk Keam, Seock-Ah Im, Kyung-Hun Lee, et al.
Cancer Research and Treatment|August 20, 2021
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast CancerJung Sun Kim, Koung Jin Suh, Dae-Won Lee, et al.
Molecular Cancer Therapeutics|March 21, 2013
RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparibAhrum Min, Seock-Ah Im, Young-Kwang Yoon, et al.
Cancer Science|November 21, 2014
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapyHee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, et al.
Breast Cancer Research and Treatment|January 24, 2019
Prognostic effects of abnormal DNA damage response protein expression in breast cancerKoung Jin Suh, Han Suk Ryu, Kyung-Hun Lee, et al.
Breast Cancer Research : BCR|July 22, 2025
MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancerCheng Hyun Lee, Soo Young Park, Jae Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2020
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with SorafenibDae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, et al.
Molecular Cancer Therapeutics|February 1, 2017
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer CellsAhrum Min, Seock-Ah Im, Hyemin Jang, et al.
Pageof 25

Showing results (161-170 of 248) with videos related to

Sort By:
Pageof 25
Cancer Chemotherapy and Pharmacology|May 16, 2013
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancerJi-Won Kim, Jee Hyun Kim, Seock-Ah Im, et al.
British Journal of Cancer|October 14, 2016
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trialsDae-Won Lee, Myoung-Jin Jang, Kyung-Hun Lee, et al.
Breast Cancer Research : BCR|March 4, 2011
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBhumsuk Keam, Seock-Ah Im, Kyung-Hun Lee, et al.
Cancer Research and Treatment|August 20, 2021
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast CancerJung Sun Kim, Koung Jin Suh, Dae-Won Lee, et al.
Molecular Cancer Therapeutics|March 21, 2013
RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparibAhrum Min, Seock-Ah Im, Young-Kwang Yoon, et al.
Cancer Science|November 21, 2014
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapyHee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, et al.
Breast Cancer Research and Treatment|January 24, 2019
Prognostic effects of abnormal DNA damage response protein expression in breast cancerKoung Jin Suh, Han Suk Ryu, Kyung-Hun Lee, et al.
Breast Cancer Research : BCR|July 22, 2025
MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancerCheng Hyun Lee, Soo Young Park, Jae Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2020
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with SorafenibDae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, et al.
Molecular Cancer Therapeutics|February 1, 2017
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer CellsAhrum Min, Seock-Ah Im, Hyemin Jang, et al.
Pageof 25